Skip to main content
Replimune Group, Inc. logo

Replimune Group, Inc. — Investor Relations & Filings

Ticker · REPL ISIN · US76029N1063 LEI · 549300AY704NEIRC4K64 US Professional, scientific and technical activities
Open in API
Filings indexed 587 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country US United States of America
Listing US REPL

About Replimune Group, Inc.

https://www.replimune.com/

Replimune Group, Inc. is a clinical-stage biotechnology company that develops oncolytic immunotherapies to treat cancer. The company's approach utilizes a proprietary platform to engineer viruses that are intended to selectively replicate within and destroy tumors while also activating a powerful, systemic, and durable anti-tumor immune response. Replimune's product candidates are being developed to treat a broad range of solid tumors, both as monotherapies and in combination with other cancer treatments. The company's mission is to revolutionize cancer treatment by inducing a comprehensive, tumor-specific immune activation.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 88% confidence The document is a Current Report on Form 8-K filed pursuant to Section 13 or 15(d) of the Securities Exchange Act, reporting a Regulation FD Disclosure (Item 7.01) and furnishing a news release as an exhibit. It does not include substantive financial statements or correspond to any specific category like earnings release, board changes, dividends, or M&A. As a general SEC regulatory announcement that doesn’t neatly fit other predefined categories, it falls under Regulatory Filings (RNS).
2026-05-29 English
4 - REPLIMUNE GROUP, INC. (0001737953) (Filer)
Director's Dealing
2026-02-20 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
10-Q Filing
Interim / Quarterly Report Q3 2026
2026-02-03 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes an amendment to a loan agreement (a material definitive agreement), a news release announcing financial results for the third fiscal quarter ended December 31, 2025, and corporate updates. It also references that the full text of the amendment will be filed as an exhibit to the upcoming Quarterly Report on Form 10-Q. The document is not itself a full quarterly report but a current report announcing specific events and updates. The presence of financial results announcement in a news release format within the 8-K aligns with a Capital/Financing Update or Earnings Release, but since the primary focus is on the loan amendment and financial obligation creation, and the earnings announcement is furnished as an exhibit rather than the main content, the best classification is Capital/Financing Update (CAP).
2026-02-03 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or updates that shareholders should know about. The text specifically mentions the release of an updated corporate presentation reflecting recent business and strategic developments and clinical data, with the presentation attached as Exhibit 99.1. The document states that the presentation will be used in meetings with analysts and investors, including at a healthcare conference. There is no detailed financial data or comprehensive report content, only an announcement and furnishing of a presentation. The length is under 5,000 characters, and the document serves to announce and provide the presentation rather than being the presentation itself or a full financial report. Therefore, this fits best as an Investor Presentation (IP) filing type, as it is a detailed presentation for investors focusing on financials, strategy, and market position, furnished as an exhibit to the Form 8-K.
2026-01-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.